xamoterol has been researched along with enoximone in 8 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (enoximone) | Trials (enoximone) | Recent Studies (post-2010) (enoximone) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 516 | 146 | 36 |
| Protein | Taxonomy | xamoterol (IC50) | enoximone (IC50) |
|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 3.95 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 3.95 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 3.95 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.95 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 3.8 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 3.8 | |
| Endothelin-1 receptor | Sus scrofa (pig) | 2.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erhardt, PW | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Hasenfuss, G; Holubarsch, C; Just, H; Thierfelder, L | 1 |
| Hasenfuss, G; Holubarsch, CH; Just, HJ; Thierfelder, L | 1 |
| Chiotti, D; Presbitero, P | 1 |
2 review(s) available for xamoterol and enoximone
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Failure; Humans; Myocardial Contraction; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1987 |
[New inotropic drugs].
Topics: Adrenergic beta-Agonists; Amrinone; Cardiotonic Agents; Deoxyepinephrine; Enoximone; Ethanolamines; Heart; Humans; Imidazoles; Milrinone; Myocardial Contraction; Propanolamines; Pyridazines; Pyridones; Vasodilator Agents; Xamoterol | 1988 |
6 other study(ies) available for xamoterol and enoximone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure.
Topics: Benzazepines; Cardiotonic Agents; Energy Metabolism; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Myocardium; Nitroprusside; Oxygen Consumption; Propanolamines; Vasodilator Agents; Xamoterol | 1991 |
Myocardial energetics in dilated cardiomyopathy.
Topics: Adrenergic beta-Agonists; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Circulation; Enoximone; Heart; Heart Failure; Heart Rate; Humans; Imidazoles; Myocardium; Nitroprusside; Oxygen Consumption; Phosphodiesterase Inhibitors; Propanolamines; Pyridazines; Stroke Volume; Vascular Resistance; Vasodilator Agents; Xamoterol | 1990 |